Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | FRK | P42685 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432587 | 1.00 | SRC (1.00) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL14617301 | 0.94 | SRC (0.89) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL409444 | 0.90 | SRC (0.82) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL29355398 | 0.88 | SRC (1.00) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL375322 | 0.88 | SRC (1.00) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL5620074 | 0.88 | SRC (0.78) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL1962682 | 0.88 | SRC (0.78) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL3610160 | 0.88 | SRC (0.95) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL3695039 | 0.88 | KDM4E (1.00) | SRCABL1RIPK2KDM4EEGFR | |
| SCHEMBL17637855 | 0.87 | SRC (0.80) | SRCABL1RIPK2KDM4EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2023-09-14 | — | — | US | claimed |
| US-20220041603-A1 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | NESTLE SA (CH) | 2022-02-10 | — | — | US | claimed |
| US-20160168151-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | claimed |
| US-20150031881-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | US | claimed |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | US | claimed |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | US | claimed |
| EP-1482983-A4 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2006-07-12 | — | — | EP | claimed |
| US-20050085472-A1 | Pyrazolo pyrimidine derivatives and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-21 | — | — | US | claimed |
| EP-1482983-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040197335-A1 | Non-myeloablative tolerogenic treatment with tyrphostins | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-10-07 | — | — | US | claimed |
| WO-2003065971-A9 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2003-11-20 | — | — | WO | claimed |
| WO-2003065971-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-14 | — | — | WO | claimed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025217247-A1 | TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-6390821-B1 | PHOSPHORYLATION | PRINCETON UNIVERSITY | 2002-05-21 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| EP-1196626-A2 | METHODS FOR IDENTIFYING INHIBITORS OF SIGNALING MOLECULES | Princeton University (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007659-A2 | METHODS FOR IDENTIFYING INHIBITORS OF SIGNALING MOLECULES | PRINCETON UNIVERSITY (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041603-A1 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | MYLK2, MUSK, SRC | SRC 3/4885ABL1 316/4885RIPK2 483/4885 |
| US-20050085472-A1 | Pyrazolo pyrimidine derivatives and methods of use thereof | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885RIPK2 2143/4885 |
| US-20160168151-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885RIPK2 2143/4885 |
| US-20150031881-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885RIPK2 2143/4885 |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885RIPK2 2143/4885 |
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | BCL9, BCL9L, BCL6B | SRC 1588/4885ABL1 84/4885RIPK2 2898/4885 |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885RIPK2 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.